BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22855754)

  • 1. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
    Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
    Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
    Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
    Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
    Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
    Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
    Aste N; Pau M; Ferreli C; Biggio P
    Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
    [No Abstract]   [Full Text] [Related]  

  • 5. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
    Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
    Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
    Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
    Brahim LR; Valete-Rosalino CM; Antônio LF; Pimentel MIF; Lyra MR; Paes LEC; Costa ADD; Vieira IF; Dias CMG; Duque MCO; Marzochi MCA; Schubach AO
    Mem Inst Oswaldo Cruz; 2017 Dec; 112(12):838-843. PubMed ID: 29211245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 11. An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
    Oliveira-Ribeiro C; Pimentel MIF; Oliveira LFA; Vasconcellos ÉCFE; Conceição-Silva F; Schubach AO; Fagundes A; de Mello CX; Mouta-Confort E; Miranda LFC; Valete-Rosalino CM; Martins ACDC; Oliveira RVC; Quintella LP; Lyra MR
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009734. PubMed ID: 34555016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
    Silva RE; Toledo A; Senna MC; Rabello A; Cota G
    Mem Inst Oswaldo Cruz; 2016 Aug; 111(8):512-6. PubMed ID: 27508321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
    Arboleda M; Barrantes S; Úsuga LY; Robledo SM
    Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
    Ramalho DB; Silva RED; Senna MCR; Moreira HSA; Pedras MJ; Avelar DM; Saraiva L; Rabello A; Cota G
    Mem Inst Oswaldo Cruz; 2018 Jun; 113(9):e180200. PubMed ID: 29947651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
    Munir A; Janjua SA; Hussain I
    Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 17. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
    Khatami A; Talaee R; Rahshenas M; Khamesipour A; Mehryan P; Tehrani S; Dowlati Y; Firooz A
    PLoS One; 2013; 8(6):e66123. PubMed ID: 23826087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
    Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ
    Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
    de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
    Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
    Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
    J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.